"Blood Screening Market by Technology (Nucleic Acid Amplification, (Real-Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%.
Browse in-depth TOC on "Blood Screening
Market"
212 – Tables
44 – Figures
235 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
The demand for donated blood is rising because of advancements
in healthcare systems and the availability of and the need for sophisticated
surgical procedures, such as cardiovascular & transplant surgery, trauma
care, and therapy for cancer and blood diseases. Emerging economies such as China, Japan, and India are
providing lucrative opportunities for the players operating in the market.
The reagents & kits segment
accounted for the largest share of the blood screening market, by product &
service segment, in 2020.
The
blood screening market is segmented into reagents & kits, instruments, and
software & services. The reagents & kits accounted for the largest
share of the market in 2020, mainly due to repeated use of reagents & kits
in blood screening procedures due to the rising blood transfusion procedures,
and the high consumption.
Nucleic Acid Test segment to
register the highest growth rate during the forecast period.
The
blood screening market is segmented into nucleic acid test (NAT), enzyme-linked
immunosorbent assay (ELISA), rapid tests, western blot assays, and
next-generation sequencing (NGS). In 2020, the nucleic acid test (NAT) segment
accounted for the largest share of the market. Factors such as the increasing
adoption of NAT technology due to its higher sensitivity over other blood
screening technologies and increasing number of blood donations.
The blood banks segment accounted
for the largest share of the blood screening, by end user segment, in 2020.
Based
on end users, the blood screening market is segmented into blood banks and
hospitals. In 2020, the blood banks segment accounted for the largest share of
the market. The growing number of organ transplantation surgeries is driving
the growth of this segment, and the increasing demand for donated blood.
Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042
North America is the largest regional
market for blood screening market.
The
global market is segmented into five major regions—north America, Europe,
the Asia
Pacific, Latin
America, and the Middle East & Africa. In
2020, North
America accounted for the largest share of the market. The
North American market growth can be attributed to the increasing healthcare
spending, increasing prevalence of chronic disorders, and the highly developed
healthcare system in the US and Canada.
The
major players operating in this blood screening market are Grifols (Spain), F.
Hoffmann-La Roche Ltd. (Switzerland),
Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories,
Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher)
(US), DiaSorin (Italy),
Siemens Healthineers (Germany),
Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE
Healthcare (US), Merck KGaA (Germany),
PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland),
Mindray (China),
Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US),
Cellabs (Australia),
Abnova Corporation (Taiwan),
Enzo Biochem, Inc. (US), and Cepheid (US).
About MarketsandMarkets™
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies'
revenues. Currently servicing 7500 customers worldwide including 80% of global
Fortune 1000 companies as clients. Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets™ for their painpoints around
revenues decisions.
Our
850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high
growth markets following the "Growth Engagement Model – GEM". The GEM
aims at proactive collaboration with the clients to identify new opportunities,
identify most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™
INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA:
+1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: -https://www.marketsandmarkets.com/ResearchInsight/blood-screening-market.asp
Content Source: - https://www.marketsandmarkets.com/PressReleases/blood-screening.asp
